Forsta AP Fonden Has $24.30 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Forsta AP Fonden cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 35,920 shares of the company’s stock after selling 2,480 shares during the quarter. Forsta AP Fonden’s holdings in IDEXX Laboratories were worth $24,301,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Beacon Investment Advisory Services Inc. lifted its position in shares of IDEXX Laboratories by 11.9% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock valued at $42,588,000 after buying an additional 6,710 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of IDEXX Laboratories by 114.1% in the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after buying an additional 8,845 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of IDEXX Laboratories by 6.8% in the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock valued at $38,477,000 after buying an additional 3,820 shares during the last quarter. Mediolanum International Funds Ltd lifted its position in shares of IDEXX Laboratories by 14.5% in the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after buying an additional 4,909 shares during the last quarter. Finally, Procyon Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $1,966,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $563.53 on Friday. The stock’s fifty day moving average price is $564.58 and its two-hundred day moving average price is $637.19. IDEXX Laboratories, Inc. has a one year low of $504.56 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market cap of $44.45 billion, a PE ratio of 41.50, a price-to-earnings-growth ratio of 3.27 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the company earned $2.91 EPS. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IDXX. Barclays cut their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Stifel Nicolaus cut their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. BTIG Research cut their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Piper Sandler lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.